XML 22 R12.htm IDEA: XBRL DOCUMENT

Accounts payable and accrued expenses

9 Months Ended

Sep. 30, 2023

5. Accounts payable and accrued expenses

Accounts payable and accrued expenses at September 30, 2023 and December 31, 2022 consist of the following:


	September 30,		December 31,
	2023		2022
Employee compensation, benefits, and related accruals	$	70,778	$	62,669
Income tax payable		2,822		4,712
Consulting and contracted research		21,236		38,882
Professional fees		3,067		3,093
Sales allowance		72,202		63,787
Sales rebates		119,971		67,355
Royalties		52,087		40,546
Accounts payable		19,152		27,268
Other		9,416		12,054
Total	$	370,731	$	320,366

During the three and nine month periods ended September 30, 2023, the Company incurred $22.6 million and $30.6 million, respectively, of restructuring costs from a reduction in workforce in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform. The costs are included in research and development and selling, general, and administrative expenses on the Company’s consolidated statement of operations. As of September 30, 2023, the remaining $23.4 million of accrued restructuring costs are included above within employee compensation, benefits, and related accruals.